Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Acquisitions Will Contribute $1.3 Bil. To 2005 Sales, Novartis Says

Executive Summary

The integration of the generic drug makers Hexal and Eon Labs into Novartis' Sandoz unit is proceeding ahead of schedule, Novartis reported

You may also be interested in...



Novartis’ “Captainship” Program Produces More Hypertension Market Share

Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market

Novartis’ “Captainship” Program Produces More Hypertension Market Share

Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market

Novartis’ New Vaccine Division Takes On Evolving Market

Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said

Related Content

Topics

UsernamePublicRestriction

Register

PS046477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel